ResearchIn-Press PreviewImmunologyOncology
Open Access |
10.1172/jci.insight.198360
1Georgia Cancer Center, Augusta University, Augusta, United States of America
2Georgia Cancer Center, Augusta Univeristy, Augusta, United States of America
Find articles by
Shi, H.
in:
PubMed
|
Google Scholar
|
1Georgia Cancer Center, Augusta University, Augusta, United States of America
2Georgia Cancer Center, Augusta Univeristy, Augusta, United States of America
Find articles by Ding, Z. in: PubMed | Google Scholar
1Georgia Cancer Center, Augusta University, Augusta, United States of America
2Georgia Cancer Center, Augusta Univeristy, Augusta, United States of America
Find articles by Okoko, O. in: PubMed | Google Scholar
1Georgia Cancer Center, Augusta University, Augusta, United States of America
2Georgia Cancer Center, Augusta Univeristy, Augusta, United States of America
Find articles by Wang, X. in: PubMed | Google Scholar
1Georgia Cancer Center, Augusta University, Augusta, United States of America
2Georgia Cancer Center, Augusta Univeristy, Augusta, United States of America
Find articles by Zhou, G. in: PubMed | Google Scholar
1Georgia Cancer Center, Augusta University, Augusta, United States of America
2Georgia Cancer Center, Augusta Univeristy, Augusta, United States of America
Find articles by Ye, Y. in: PubMed | Google Scholar
1Georgia Cancer Center, Augusta University, Augusta, United States of America
2Georgia Cancer Center, Augusta Univeristy, Augusta, United States of America
Find articles by Gazi, M. in: PubMed | Google Scholar
1Georgia Cancer Center, Augusta University, Augusta, United States of America
2Georgia Cancer Center, Augusta Univeristy, Augusta, United States of America
Find articles by Brandle, C. in: PubMed | Google Scholar
1Georgia Cancer Center, Augusta University, Augusta, United States of America
2Georgia Cancer Center, Augusta Univeristy, Augusta, United States of America
Find articles by Pei, L. in: PubMed | Google Scholar
1Georgia Cancer Center, Augusta University, Augusta, United States of America
2Georgia Cancer Center, Augusta Univeristy, Augusta, United States of America
Find articles by Pacholczyk, R. in: PubMed | Google Scholar
1Georgia Cancer Center, Augusta University, Augusta, United States of America
2Georgia Cancer Center, Augusta Univeristy, Augusta, United States of America
Find articles by Hedrick, C. in: PubMed | Google Scholar
1Georgia Cancer Center, Augusta University, Augusta, United States of America
2Georgia Cancer Center, Augusta Univeristy, Augusta, United States of America
Find articles by Bryan, L. in: PubMed | Google Scholar
1Georgia Cancer Center, Augusta University, Augusta, United States of America
2Georgia Cancer Center, Augusta Univeristy, Augusta, United States of America
Find articles by Zhou, G. in: PubMed | Google Scholar
Published April 7, 2026 - More info
Cytotoxic chemotherapy primarily targets rapidly proliferating cancer cells but also depletes normal myeloid cells. The resulting cell loss triggers reactive myelopoiesis, a compensatory process in which hematopoietic stem and progenitor cells (HSPCs) in the bone marrow (BM) regenerate myeloid lineages. We previously showed that the alkylating agent cyclophosphamide (CTX) induces myelopoiesis leading to the expansion of immunosuppressive monocytes in mice. However, the molecular features and clinical relevance of these cells remain poorly understood. Here, we report the emergence of immunosuppressive monocytes in the peripheral blood of lymphoma patients receiving CTX-containing chemotherapy. To gain mechanistic insight into CTX-induced myelopoiesis, we performed single-cell RNA sequencing (scRNA-seq) and assay for transposase-accessible chromatin using sequencing (ATAC-seq) on BM monocytes from CTX-treated mice. These analyses revealed a heterogeneous monocyte population and demonstrated that CTX skews myelopoiesis toward the generation of neutrophil-like monocytes (NeuMo). Moreover, CTX-induced NeuMo cells, enriched within the CXCR4⁺CX3CR1⁻ monocyte subset, exhibited potent T-cell suppressive activity. Using the NeuMo gene signature, reanalysis of public scRNA-seq datasets identified a transcriptionally similar monocyte subset in chemotherapy-treated cancer patients. Collectively, our findings suggest that the expansion of NeuMo-like cells following chemotherapy represents a conserved immunoregulatory feedback mechanism with potential impact on tumor response to chemoimmunotherapy.